Results 221 to 230 of about 212,106 (307)

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma. [PDF]

Int J Mol Sci
Hughes E, Latham S, Kuss B, Grist S, Hall R, Khong T, Gorniak M, Spencer A, Tam C, Mulligan S, Bailey S, Sartor M, Carney D, Cull G, Gottlieb D, Morley A.   +15 more
europepmc   +1 more source

Figure 2 from Serially Quantifying <i>TERT</i> Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma

Jan F. Hollander, Annabell Szymansky, Jasmin Wünschel, Kathy Astrahantseff, Carolina Rosswog, Anne Thorwarth, Theresa M. Thole-Kliesch, Rocío Chamorro González, Patrick Hundsdörfer, Kathrin Hauptmann, Karin Schmelz, Dennis Gürgen, Julian M.M. Rogasch, Anton G. Henssen, Matthias Fischer, Johannes H. Schulte, Cornelia Eckert, Angelika Eggert, Marco Lodrini, Hedwig E. Deubzer   +19 more
openalex   +1 more source

Minimal Residual Disease Persistence [PDF]

, 2020
openaire   +1 more source

Pioglitazone plus (−)‐epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells

FEBS Open Bio, EarlyView.
Aged human bmMSCs are seeded in the scaffold. Osteoblastic induction can slightly increase cell's bone‐forming activity to produce bone‐like tissues, shown as the sporadic xylenol orange‐stained spots (the lower left image). Notably, pioglitazone plus EGCG co‐treatment dramatically increases cell's bone‐forming activity and bone‐like tissue production (
Ching‐Yun Chen, Jia‐Ci Jhang, Chun‐Yi Peng, Quốc Cường Nguyễn, Feng‐Huei Lin, Hung‐Ming Wu, Shankung Lin   +6 more
wiley   +1 more source

Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20. [PDF]

Ann Hematol
Cecchi N, Sciumè M, Ricchiuti A, Bosi A, Tagliaferri E, Passamonti F, Fracchiolla NS.   +6 more
europepmc   +1 more source

Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia (ALL): Impact of Conditioning Intensity, Tyrosine Kinase Inhibitors (TKI) and Minimal Residual Disease (MRD)

, 2013
Veronika Bachanová, David I. Marks, Mei‐Jie Zhang, Hailin Wang, Daniel J. Weisdorf   +4 more
openalex   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. [PDF]

MedComm (2020)
Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, Wang Z, Deng Y, He N, Liu H, Li S.   +10 more
europepmc   +1 more source

Minimal Residual Disease-guided Therapy in Adult Ph (-) Acute Lymphoblastic Leukemia

, 2019
Koji Nagafuji
openalex   +2 more sources

Understanding bio‐based polymers: A study of origins, properties, biodegradation and their impact on health and the environment

FEBS Open Bio, EarlyView.
This review provides an overview of bio‐based polymer sources, their unique functional properties and their environmental impact, and addresses their role as sustainable alternatives. It discusses end‐of‐life options, including composting and anaerobic digestion for renewable energy.
Sabina Kolbl Repinc, Blaž Stres, Mirica Karlovits, Igor Karlovits, Petra Jerič, Ondrej Panák, Anja Verbič, Blaž Likozar, Uroš Novak   +8 more
wiley   +1 more source